Dorzolamide

Dorzolamide

SCHEMBL4525137

CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CA2

The experimentally established mechanism targets of Dorzolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 18/20 1.00
CA1 P00915 3/20 1.00
CA12 O43570 1/20 1.00
CA3 P07451 1/20 1.00
AR P10275 1/20 1.00
CA4 P22748 1/20 1.00
CA6 P23280 1/20 1.00
CA5A P35218 1/20 1.00
CA7 P43166 1/20 1.00
CA9 Q16790 1/20 1.00
CA13 Q8N1Q1 1/20 1.00
CA14 Q9ULX7 1/20 1.00
CA5B Q9Y2D0 1/20 1.00
LMNA P02545 1/20 1.00
TSHR P16473 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dorzolamide SCHEMBL9914274 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL24061 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12453422 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12874119 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL3306381 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL4455530 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12223216 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL9914275 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL3314050 0.99 CA2 (0.98) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL28388851 0.99 CA2 (0.98) CA2CA1CA12CA3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198316-B2 Process for the preparation of 5,6 -dihydro -4H-4(S)-ethylamino-6(S)-methylthieno[2,3-b] thiopyran-2-sulfonamide- 7,7 -dioxide and its salt FDC LTD (IN) 2012-06-12 US claimed
EP-0258184-A2 Quinoline derivatives as herbicide antagonists for cultivated plants CIBA-GEIGY AG (CH) 1988-03-02 EP claimed
WO-2025004579-A1 OPHTHALMIC COMPOSITION 株式会社ニデック 2025-01-02 WO disclosed
US-11559508-B2 Pharmaceutical compositions comprising POH derivatives and methods of use Neonc Technologies, Inc. (US) 2023-01-24 US disclosed
US-20200237697-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE UNIVERSITY OF SOUTHERN CALIFORNIA 2020-07-30 US disclosed
US-8263787-B2 Process for preparing dorzolamide CIPLA LIMITED (IN) 2012-09-11 US disclosed
US-8198316-B2 Process for the preparation of 5,6 -dihydro -4H-4(S)-ethylamino-6(S)-methylthieno[2,3-b] thiopyran-2-sulfonamide- 7,7 -dioxide and its salt FDC LTD (IN) 2012-06-12 US disclosed
US-8198316-B2 Process for the preparation of 5,6 -dihydro -4H-4(S)-ethylamino-6(S)-methylthieno[2,3-b] thiopyran-2-sulfonamide- 7,7 -dioxide and its salt FDC LTD (IN) 2012-06-12 US disclosed
US-20100113804-A1 Process for Preparing Dorzolamide CIPLA LIMITED (IN) 2010-05-06 US disclosed
US-20090264662-A1 PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT FDC LTD (IN) 2009-10-22 US disclosed
EP-0296879-B1 SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS MERCK & CO. INC. (US) 1993-03-17 EP disclosed
US-4863922-A Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use MERCK & CO., INC. (US) 1989-09-05 US disclosed
EP-0296879-A1 Substituted aromatic sulfonamides as antiglaucoma agents MERCK & CO. INC. (US) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113804-A1 Process for Preparing Dorzolamide SQOR, PPOX, DAO CA2 605/4885CA1 196/4885CA12 969/4885
US-11559508-B2 Pharmaceutical compositions comprising POH derivatives and methods of use ACADVL, CPT1A, ADH5 CA2 3013/4885CA1 1053/4885CA12 425/4885
US-20200237697-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE ACADVL, CPT1A, ADH5 CA2 3013/4885CA1 1053/4885CA12 425/4885
US-20090264662-A1 PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT DHODH, SPR, TST CA2 353/4885CA1 644/4885CA12 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.